95086-96-7

Basic information

• Product Name: Benzamide, N-(2-methoxyethyl)-4-nitro-
• Synonyms: 4-nitro-benzoic acid-(2-methoxy-ethylamide);N-[2-(methyloxy)ethyl]-4-nitrobenzamide;4-Nitro-benzoesaeure-(2-methoxy-aethylamid);N--(2-methoxyethyl)-4-nitrobenzamide;N-(2-Methoxy-aethyl)-4-nitro-benzamid;N-(2-methoxyethyl)-p-nitrobenzamide
• CAS NO: 95086-96-7
• Molecular Formula: C10H12N2O4
• Molecular Weight: 224.216
• Mol File: 95086-96-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzamide, N-(2-methoxyethyl)-4-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-(2-methoxyethyl)-4-nitro-(95086-96-7)
• EPA Substance Registry System: Benzamide, N-(2-methoxyethyl)-4-nitro-(95086-96-7)

Safety Data

• Hazardous Substances Data: 95086-96-7(Hazardous Substances Data)

Upstream product

• 109-85-3 2-methoxyethylamine 
• 62-23-7 4-nitro-benzoic acid 
• 67-56-1 methanol 
• 19614-29-0 1-(p-nitrobenzoyl)aziridine 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 1316066-55-3 4-[(6-chloro-4-pyrimidinyl)amino]-N-[2-(methyloxy)ethyl]benzamide 
• 1395885-91-2 N₄-(2-chlorophenyl)-N₂-[4-N-(2-methoxyethyl)carbamoylphenyl]pyrimidine-2,4-diamine hydrochloride 
• 95086-97-8 N-(2-methoxyethyl)-p-aminobenzamide 

Relevant articles and documents

Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors

The o-carboxylic acid substituted bisanilinopyrimidine 1 was identified as a potent hit (Aurora A IC50 = 6.1 ± 1.0 nM) from in-house screening. Detailed structure-activity relationship (SAR) studies indicated that polar substituents at the para position of the B-ring are critical for potent activity. X-ray crystallography studies revealed that compound 1 is a type I inhibitor that binds the Aurora kinase active site in a DFG-in conformation. Structure-activity guided replacement of the A-ring carboxylic acid with halogens and incorporation of fluorine at the pyrimidine 5-position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation. B-Ring modifications were undertaken to improve the solubility and cell permeability. Compounds such as 9m with water-solubilizing moieties at the para position of the B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.

COMPOUNDS AND METHODS

Disclosed are compounds having the formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined herein, and methods of making and using the same.

PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.